Abstract
Background and Aims: The discovery of the anti-tumor effect of 1,25-dihydroxyvitamin D3 (1,25-D3) on various malignancies, including hepatocellular carcinoma (HCC), suggested that a new treatment opportunity may exist. The use of 1,25-D3 analogs without hypercalcemic effects is the subject of preclinical and clinical studies. Increased activity of 24-hydroxylase (CYP24A1), the key enzyme neutralizing of 1,25-D3, has been found in colon, lung, prostate, thyroid, breast, and ovarian cancer cells. In a previous study we found increased CYP24A1 mRNA expression following 1,25-D3 administration in HCC cell lines in vitro. Therefore, we investigated CYP24A1 mRNA and also the 1,25-D3-activating 1-alpha-hydroxylase (CYP27B1) mRNA in human HCC samples.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
